Assessment of Grazax® Treatment Compliance - Full Text View

Sponsored by:	ALK-Abelló A/S
Information provided by:	ALK-Abelló A/S
ClinicalTrials.gov Identifier:	NCT00293046

Purpose

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Condition	Intervention	Phase
Allergy	Biological: ALK Grass tablet - use of compliance device	Phase III

MedlinePlus related topics: Allergy

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Parallel Assignment
Official Title:	A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	500
Study Start Date:	February 2006
Study Completion Date:	October 2007
Primary Completion Date:	September 2006 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00293046

Locations

Austria
Allgergie - Ambulatorium Rennweg
Wien, Austria, 1030

Sponsors and Collaborators

ALK-Abelló A/S

Investigators

Study Director:

Kim Simonsen, MD

ALK-Abelló A/S

More Information

Study ID Numbers:	GT-10
Study First Received:	February 16, 2006
Last Updated:	September 29, 2008
ClinicalTrials.gov Identifier:	NCT00293046
Health Authority:	Denmark: Danish Medicines Agency; Austria: Federal Ministry for Health and Women; Sweden: Medical Products Agency; Netherlands: Medicines Evaluation Board (MEB); Germany: Paul-Ehrlich-Institut

Keywords provided by ALK-Abelló A/S:

Allergy

Study placed in the following topic categories:

Hypersensitivity

ClinicalTrials.gov processed this record on January 14, 2009